Quarterly Activity Report and Appendix 4C for Q2 FY2025
| Stock | 4DMEDICAL Ltd (4DX.ASX) |
|---|---|
| Release Time | 29 Jan 2025, 8:23 a.m. |
| Price Sensitive | Yes |
4DMedical Reports Q2 FY2025 Results, Highlights Strong Growth
- Q2 FY2025 operating revenue up 202% on prior year
- 4DMedical now operating at 301 sites, up 24% from 2H FY2024
- Delivered over 8,000 scans in 1H FY2025, up 77% on prior year
4DMedical Limited, a respiratory imaging technology company, announced its Quarterly Activity Report and Appendix 4C Cash Flow Report for the quarter ended 31 December 2024. The company reported strong financial and operational performance, with Q2 FY2025 operating revenue of $1.5 million, up 202% on the prior corresponding period. SaaS revenue for 1H FY2025 was $2.9 million, up 16.5% from 2H FY2024. 4DMedical is now delivering SaaS products at 301 sites globally, up from 242 sites in 2H FY2024 (24% growth), and up 41% on the prior corresponding period. The company delivered over 8,000 scans in 1H FY2025, up 37% from 2H FY2024 and 77% on the prior corresponding period. Sales of core 4DMedical XV Technology® products grew strongly at 106% in Q2 FY2025 on the prior corresponding period, in addition to strong growth in price per scan earned for core XV Technology® products. The company also received $7.7 million in grant funding, including the R&D tax incentive and final instalment of the MRFF grant. 4DMedical continued to build momentum with the implementation of the Philips reseller agreement, and announced several new key partnerships with leading healthcare providers in the U.S. and Australia. The company also received FDA clearance for its IQ-UIP™ product, an advanced AI-driven lung diagnostic tool, and made significant progress with its CT:VQ™ technology, which is set to disrupt the billion-dollar segment of respiratory diagnostics.
4DMedical expects continued strong growth in its SaaS revenue, with the company's core XV Technology® products and the upcoming launch of CT:VQ™ technology providing significant revenue opportunities in FY2025 and beyond.
The company is well-positioned for continued growth, with the implementation of the Philips reseller agreement, the launch of new products like CT:VQ™, and the expansion of its partnerships with leading healthcare providers in the U.S. and Australia.